Prescient Therapeutics Ltd
ASX:PTX
Prescient Therapeutics Ltd
ASX:PTX
Price:
0.048 AUD
-4%
Market Closed
Updated:
May 2, 2024
Prescient Therapeutics Ltd
Net Income (Common)
|
Prescient Therapeutics Ltd
Net Income (Common) Peer Comparison
Comparables:
IMM
MSB
CSL
CUV
TLX
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Prescient Therapeutics Ltd
ASX:PTX
|
Net Income (Common)
-AU$7.7m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-21%
|
|
|
Immutep Ltd
ASX:IMM
|
Net Income (Common)
-AU$40.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-12%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Net Income (Common)
-$73.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Net Income (Common)
$2.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Net Income (Common)
AU$30.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Net Income (Common)
AU$5.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Prescient Therapeutics Ltd's Net Income (Common)?
Net Income (Common)
-7.7m
AUD
-7.7m
AUD
Based on the financial report for Dec 31, 2023, Prescient Therapeutics Ltd's Net Income (Common) amounts to -7.7m AUD.
What is Prescient Therapeutics Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-21%
-21%
Over the last year, the Net Income (Common) growth was -44%. The average annual Net Income (Common) growth rates for Prescient Therapeutics Ltd have been -31% over the past three years , -21% over the past five years , and -21% over the past ten years .
You don't have any saved screeners yet
